<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03364738</url>
  </required_header>
  <id_info>
    <org_study_id>SHP634-404</org_study_id>
    <secondary_id>2017-003067-36</secondary_id>
    <nct_id>NCT03364738</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism</brief_title>
  <official_title>An Open-label Study Investigating the Safety and Efficacy of rhPTH(1-84) in Subjects With Hypoparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is open to adults with hypoparathyroidism who complete the SHP634-101 study&#xD;
      (PARALLAX Study). The purpose of this study is to see if rhPTH(1-84) is safe and effective in&#xD;
      adults with hypoparathyroidism who previously participated in the SHP634-101 study. All&#xD;
      participants enrolled in this study will receive rhPTH(1-84) once-daily for 52 weeks via an&#xD;
      injection.&#xD;
&#xD;
      Patients who complete the SHP634-101 study will have the option to screen for this extension&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to Takeda commercial Natpara recall.&#xD;
  </why_stopped>
  <start_date type="Actual">September 26, 2018</start_date>
  <completion_date type="Actual">April 14, 2020</completion_date>
  <primary_completion_date type="Actual">April 14, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieved Total Albumin-corrected Serum Calcium (ACSC) Values Greater Than or Equal to (&gt;=) to the Range of 7.5 mg/dL (1.875 mmol/L) and Less Than or Equal to (&lt;=) Upper Limit of Normal (ULN) at Week 24</measure>
    <time_frame>At Week 24</time_frame>
    <description>Percentage of participants who achieved ACSC values &gt;= to range of 1.875 mmol/L and &lt;= ULN at Week 24 was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Total ACSC Values &gt;= to the Range of 7.5 mg/dL (1.875 mmol/L) and &lt;=ULN at Week 52 (End-of-treatment [EOT])</measure>
    <time_frame>At Week 52 (EOT)</time_frame>
    <description>Percentage of participants who achieved ACSC values &gt;= to range of 1.875 mmol/L and &lt;= ULN at Week 52 (EOT) was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs</measure>
    <time_frame>From start of study drug administration to end of study (Week 56)</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A Serious Adverse Event (SAE) was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, and is an important medical event. TEAEs were defined as AEs with a start date on or after the first dose of investigational product or a start date before the date of the first dose of investigational product that increased in severity or after the date of the first dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Clinical Laboratory Values</measure>
    <time_frame>From start of study drug administration to end of study (Week 56)</time_frame>
    <description>Clinical laboratory assessment included hematology, serum chemistry, urine chemistry and urinalysis. Clinical significance was judged by the investigator based upon the out of range values of standard range set for each parameter. Any changes in clinical laboratory results which were deemed clinically significant by the investigator was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Vital Sign</measure>
    <time_frame>From start of study drug administration to end of study (Week 56)</time_frame>
    <description>Vital sign parameters included: temperature, pulse rate, respiration rate, systolic and diastolic blood pressure. Clinical significance was judged by the investigator based upon the out of range values of standard range set for each parameter. Any changes in vital signs which were deemed clinically significant by the investigator was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Parameters</measure>
    <time_frame>From start of study drug administration to end of study (Week 56)</time_frame>
    <description>Twelve-lead ECGs was performed in triplicate with a minimum 2-minute gap between traces. The participant rested in the supine position for at least 5 minutes before collecting the ECG. Assessment of ECG parameters included: heart rate, RR interval, PR interval, QRS interval, QT interval, and QTc interval. Clinical significance was judged by the investigator based upon the out of range values of standard range set for each parameter. Any change in ECG assessments which were deemed clinically significant by the investigator was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Estimated Glomerular Filtration Rate (eGFR) Values</measure>
    <time_frame>From start of study drug administration to end of study (Week 56)</time_frame>
    <description>eGFR was calculated using the chronic kidney disease epidemiology (CDK-epi) formula. Clinical significance was judged by the investigator based upon the out of range values of standard range set for parameter. Any change in eGFR assessments which were deemed clinically significant by the investigator was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Serum Creatinine Value</measure>
    <time_frame>From start of study drug administration to end of study (Week 56)</time_frame>
    <description>eGFR was assessed by measuring serum creatinine. Serum creatinine level was obtained directly from laboratory results. Clinical significance was judged by the investigator based upon the out of range values of standard range set for parameter. Any change in serum creatinine assessments which were deemed clinically significant by the investigator was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Positive Anti-Parathyroid Hormone Antibodies at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Number of participants with positive anti-parathyroid hormone antibodies at Week 24 was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Positive Anti-Parathyroid Hormone Antibodies at Week 52 (EOT)</measure>
    <time_frame>Week 52 (EOT)</time_frame>
    <description>Number of participants with positive anti-parathyroid hormone antibodies at Week 52 (EOT) was reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Albumin Corrected Serum Calcium (ACSC) Concentration at Weeks 24 and 52 (EOT)</measure>
    <time_frame>Baseline, Weeks 24 and 52 (EOT)</time_frame>
    <description>Change from baseline in ACSC concentration at Weeks 24 and 52 (EOT) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Phosphate Concentration at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)</measure>
    <time_frame>Baseline, Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)</time_frame>
    <description>Change from baseline in serum phosphate concentration at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ACSC-phosphate Product at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)</measure>
    <time_frame>Baseline, Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)</time_frame>
    <description>Change from baseline in ACSC-phosphate product at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT) was reported. Here &quot;mmol^2/L^2&quot; is abbreviated as millimoles square per liter square.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24-hour Urine Calcium Excretion at Weeks 16, 32 and 52 (EOT)</measure>
    <time_frame>Baseline, Weeks 16, 32 and 52 (EOT)</time_frame>
    <description>Change from baseline in 24-hour urine calcium excretion at Weeks 16, 32 and 52 (EOT) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Prescribed Supplemental Oral Calcium Dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (End of Study [EOS])</measure>
    <time_frame>Baseline and at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS)</time_frame>
    <description>Percentage change from baseline in prescribed supplemental oral calcium dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS) were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Prescribed Supplemental Active Vitamin D Dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS)</measure>
    <time_frame>Baseline, Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS)</time_frame>
    <description>Percentage change from baseline in prescribed supplemental oral calcium dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS) were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Serum Bone-specific Alkaline Phosphatase at Weeks 8, 24 and 52 (EOT)</measure>
    <time_frame>Baseline, Weeks 8, 24 and 52 (EOT)</time_frame>
    <description>Percentage change from baseline in serum bone-specific alkaline phosphatase at Weeks 8, 24 and 52 (EOT) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Serum Osteocalcin at Weeks 8, 24 and 52 (EOT)</measure>
    <time_frame>Baseline, Weeks 8, 24 and 52 (EOT)</time_frame>
    <description>Percentage change from baseline in serum osteocalcin at Weeks 8, 24 and 52 (EOT) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Procollagen 1 N-Terminal Propeptide at Weeks 8, 24 and 52 (EOT)</measure>
    <time_frame>Baseline, Weeks 8, 24 and 52 (EOT)</time_frame>
    <description>Percentage change from baseline in procollagen 1 N-terminal propeptide at Weeks 8, 24 and 52 (EOT) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Type I Collagen C-Telopeptides at Weeks 8, 24 and 52 (EOT)</measure>
    <time_frame>Baseline, Weeks 8, 24 and 52 (EOT)</time_frame>
    <description>Percentage change from baseline in type I collagen C-telopeptides at Week 8, 24 and 52 (EOT) was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Type I Collagen N-Telopeptides at Weeks 8, 24 and 52 (EOT)</measure>
    <time_frame>Baseline, Weeks 8, 24 and 52 (EOT)</time_frame>
    <description>Percentage change from baseline in type I collagen N-telopeptides at Week 8, 24 and 52 (EOT) was reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Hypoparathyroidism</condition>
  <arm_group>
    <arm_group_label>rhPTH(1-84)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive rhPTH(1-84) subcutaneous (SC) injection in the thigh (alternate thigh every day) once daily (QD) of an escalating dose from 50 microgram (mcg) to a maximum of 100 mcg increased in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining albumin-corrected serum calcium (ACSC) levels in the range of 2-2.25 millimoles per liter (mmol/L) (8.0-9.0 milligrams per deciliter [mg/dL]). Once a participant achieves a stable ACSC (2-2.25 mmol/L [8.0-9.0mg/dL]) and has minimized supplement doses, they will be maintained at that dose of rhPTH(1-84). If ACSC is greater than (&gt;) 2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rhPTH(1-84)</intervention_name>
    <description>Participants will receive rhPTH(1-84) SC injection in the thigh (alternate thigh every day) QD.</description>
    <arm_group_label>rhPTH(1-84)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  An understanding, ability, and willingness to fully comply with study procedures and&#xD;
             restrictions&#xD;
&#xD;
          -  Ability to voluntarily provide written, signed, and dated informed consent to&#xD;
             participate in the study.&#xD;
&#xD;
          -  Previously completed the SHP634-101 (NCT02781844) study, including the 30-day&#xD;
             follow-up.&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating female subjects who agree to comply with&#xD;
             applicable contraceptive requirements of the protocol or females of non-childbearing&#xD;
             potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received investigational study drug, aside from that received in study SHP634-101&#xD;
             (NCT02781844), within 3 months prior to the screening visit.&#xD;
&#xD;
          -  Presence or history of a clinically significant disorder involving the cardiovascular,&#xD;
             respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine (with&#xD;
             exception of the condition under study), or neurologic system(s) or psychiatric&#xD;
             disease, that in the opinion of the investigator, would make the subject unsuitable&#xD;
             for this study.&#xD;
&#xD;
          -  Received parathyroid hormone (PTH), PTH analog, or parathyroid hormone fragment 1-34&#xD;
             [PTH(1-34)] treatment within the last 30 days from the screening visit.&#xD;
&#xD;
          -  Subjects with a history of parathyroid hormone intolerance, based on investigator&#xD;
             determination.&#xD;
&#xD;
          -  Any disease that might affect calcium metabolism or calcium-phosphate homeostasis as&#xD;
             determined by the investigator other than hypoparathyroidism, including but not&#xD;
             limited to, active hyperthyroidism; poorly controlled insulin-dependent diabetes&#xD;
             mellitus or type 2 diabetes mellitus; severe and chronic cardiac, liver or renal&#xD;
             disease; Cushing's syndrome; neuromuscular disease such as rheumatoid arthritis;&#xD;
             myeloma; pancreatitis; malnutrition; rickets; recent prolonged immobility; active&#xD;
             malignancy, bone metastases or a history of skeletal malignancies; primary or&#xD;
             secondary hyperparathyroidism; a history of parathyroid carcinoma; hypopituitarism,&#xD;
             acromegaly; or multiple endocrine neoplasia types 1 and 2 .&#xD;
&#xD;
          -  Subjects who are at increased baseline risk for osteosarcoma such as subjects with&#xD;
             Paget's disease of bone or unexplained elevations of alkaline phosphatase, young adult&#xD;
             subjects with open epiphyses, subjects with hereditary disorders predisposing to&#xD;
             osteosarcoma or subjects with a prior history of external beam or implant radiation&#xD;
             therapy involving the skeleton.&#xD;
&#xD;
          -  Use of the following medications prior to administration of investigational product&#xD;
             within:&#xD;
&#xD;
               1. 30 days-loop diuretics, lithium, systemic corticosteroids (medical judgment is&#xD;
                  required by the investigator. Primarily high doses of systemic corticosteroids&#xD;
                  [example (eg), prednisone] should be excluded. Stable doses of hydrocortisone&#xD;
                  [eg, as treatment for Addison's disease] may be acceptable).&#xD;
&#xD;
               2. 3 months-cinacalcet hydrochloride&#xD;
&#xD;
               3. 6 months-fluoride tablets, oral bisphosphonates, methotrexate, growth hormone,&#xD;
                  digoxin&#xD;
&#xD;
               4. 12 months-intravenous bisphosphonates, drug or alcohol abuse, as determined by&#xD;
                  the investigator&#xD;
&#xD;
          -  Presence of any clinically significant results from laboratory tests, vital signs&#xD;
             assessments, or electrocardiograms (ECG), that in the opinion of the investigator,&#xD;
             would make the subject unsuitable for this study.&#xD;
&#xD;
          -  Any medical condition or prior therapy that, in the opinion of the investigator, would&#xD;
             make the subject unsuitable for this study.&#xD;
&#xD;
          -  History of a clinically significant illness during the 4 weeks prior to dosing, that&#xD;
             in the opinion of the investigator, would make the subject unsuitable for this study.&#xD;
&#xD;
          -  History of any clinically significant surgery or procedure within 8 weeks of first&#xD;
             dose, as determined by the investigator or expected to undergo a major surgical&#xD;
             procedure during the trial.&#xD;
&#xD;
          -  History of an allergic response(s) to PTH, PTH analogs, or PTH(1-34), or other&#xD;
             clinically significant allergies, that in the opinion of the investigator, would make&#xD;
             the subject unsuitable for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crescent City Clinical Research Center, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Nevada Endocrinology - Lisa Abbott MD</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511-2060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University, Jefferson Rheumatology Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-6810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bone Research and Education Centre</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6M 1M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec-Universite Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem, I. sz. Belgyogyaszati Klinika</name>
      <address>
        <city>PÃ©cs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Hungary</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2017</study_first_posted>
  <results_first_submitted>April 14, 2021</results_first_submitted>
  <results_first_submitted_qc>May 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 16, 2021</results_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03364738/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03364738/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with hypoparathyroidism (HPT) who completed SHP634-101 (NCT02781844) study were eligible and enrolled in this extension study which was conducted at 10 sites in the United States, Denmark, Hungary and Canada between 26 September 2018 (first participant first visit) and 14 April 2020 (last participant last visit).</recruitment_details>
      <pre_assignment_details>A total of 22 participants were enrolled and treated in the study, of which 14 participants completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>rhPTH(1-84)</title>
          <description>Participants received recombinant human parathyroid hormone (rhPTH) (1-84) (Natpara) 50 microgram (mcg), injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (end of treatment [EOT])/ early termination (ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining albumin-corrected serum calcium (ACSC) levels in the range of 2-2.25 millimoles per liter (mmol/L) (8-9 milligrams per deciliter [mg/dL]). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was greater than (&gt;) 2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Early termination due to Food and Drug Administration recall of rhPTH(1-84) (Natpara)</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis population consisted of all participants who have received at least 1 dose of rhPTH(1-84).</population>
      <group_list>
        <group group_id="B1">
          <title>rhPTH(1-84)</title>
          <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="11.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native American And Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieved Total Albumin-corrected Serum Calcium (ACSC) Values Greater Than or Equal to (&gt;=) to the Range of 7.5 mg/dL (1.875 mmol/L) and Less Than or Equal to (&lt;=) Upper Limit of Normal (ULN) at Week 24</title>
        <description>Percentage of participants who achieved ACSC values &gt;= to range of 1.875 mmol/L and &lt;= ULN at Week 24 was reported.</description>
        <time_frame>At Week 24</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;overall number of participants analyzed&quot; were participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Total Albumin-corrected Serum Calcium (ACSC) Values Greater Than or Equal to (&gt;=) to the Range of 7.5 mg/dL (1.875 mmol/L) and Less Than or Equal to (&lt;=) Upper Limit of Normal (ULN) at Week 24</title>
          <description>Percentage of participants who achieved ACSC values &gt;= to range of 1.875 mmol/L and &lt;= ULN at Week 24 was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;overall number of participants analyzed&quot; were participants who were evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Total ACSC Values &gt;= to the Range of 7.5 mg/dL (1.875 mmol/L) and &lt;=ULN at Week 52 (End-of-treatment [EOT])</title>
        <description>Percentage of participants who achieved ACSC values &gt;= to range of 1.875 mmol/L and &lt;= ULN at Week 52 (EOT) was reported.</description>
        <time_frame>At Week 52 (EOT)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84).</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Total ACSC Values &gt;= to the Range of 7.5 mg/dL (1.875 mmol/L) and &lt;=ULN at Week 52 (End-of-treatment [EOT])</title>
          <description>Percentage of participants who achieved ACSC values &gt;= to range of 1.875 mmol/L and &lt;= ULN at Week 52 (EOT) was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" lower_limit="0.772" upper_limit="0.999"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A Serious Adverse Event (SAE) was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, and is an important medical event. TEAEs were defined as AEs with a start date on or after the first dose of investigational product or a start date before the date of the first dose of investigational product that increased in severity or after the date of the first dose.</description>
        <time_frame>From start of study drug administration to end of study (Week 56)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84).</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A Serious Adverse Event (SAE) was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, and is an important medical event. TEAEs were defined as AEs with a start date on or after the first dose of investigational product or a start date before the date of the first dose of investigational product that increased in severity or after the date of the first dose.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Change in Clinical Laboratory Values</title>
        <description>Clinical laboratory assessment included hematology, serum chemistry, urine chemistry and urinalysis. Clinical significance was judged by the investigator based upon the out of range values of standard range set for each parameter. Any changes in clinical laboratory results which were deemed clinically significant by the investigator was reported.</description>
        <time_frame>From start of study drug administration to end of study (Week 56)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84).</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change in Clinical Laboratory Values</title>
          <description>Clinical laboratory assessment included hematology, serum chemistry, urine chemistry and urinalysis. Clinical significance was judged by the investigator based upon the out of range values of standard range set for each parameter. Any changes in clinical laboratory results which were deemed clinically significant by the investigator was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Change in Vital Sign</title>
        <description>Vital sign parameters included: temperature, pulse rate, respiration rate, systolic and diastolic blood pressure. Clinical significance was judged by the investigator based upon the out of range values of standard range set for each parameter. Any changes in vital signs which were deemed clinically significant by the investigator was reported.</description>
        <time_frame>From start of study drug administration to end of study (Week 56)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84).</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT])/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change in Vital Sign</title>
          <description>Vital sign parameters included: temperature, pulse rate, respiration rate, systolic and diastolic blood pressure. Clinical significance was judged by the investigator based upon the out of range values of standard range set for each parameter. Any changes in vital signs which were deemed clinically significant by the investigator was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Parameters</title>
        <description>Twelve-lead ECGs was performed in triplicate with a minimum 2-minute gap between traces. The participant rested in the supine position for at least 5 minutes before collecting the ECG. Assessment of ECG parameters included: heart rate, RR interval, PR interval, QRS interval, QT interval, and QTc interval. Clinical significance was judged by the investigator based upon the out of range values of standard range set for each parameter. Any change in ECG assessments which were deemed clinically significant by the investigator was reported.</description>
        <time_frame>From start of study drug administration to end of study (Week 56)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84).</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT])/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Parameters</title>
          <description>Twelve-lead ECGs was performed in triplicate with a minimum 2-minute gap between traces. The participant rested in the supine position for at least 5 minutes before collecting the ECG. Assessment of ECG parameters included: heart rate, RR interval, PR interval, QRS interval, QT interval, and QTc interval. Clinical significance was judged by the investigator based upon the out of range values of standard range set for each parameter. Any change in ECG assessments which were deemed clinically significant by the investigator was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Change in Estimated Glomerular Filtration Rate (eGFR) Values</title>
        <description>eGFR was calculated using the chronic kidney disease epidemiology (CDK-epi) formula. Clinical significance was judged by the investigator based upon the out of range values of standard range set for parameter. Any change in eGFR assessments which were deemed clinically significant by the investigator was reported.</description>
        <time_frame>From start of study drug administration to end of study (Week 56)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84).</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT])/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change in Estimated Glomerular Filtration Rate (eGFR) Values</title>
          <description>eGFR was calculated using the chronic kidney disease epidemiology (CDK-epi) formula. Clinical significance was judged by the investigator based upon the out of range values of standard range set for parameter. Any change in eGFR assessments which were deemed clinically significant by the investigator was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Change in Serum Creatinine Value</title>
        <description>eGFR was assessed by measuring serum creatinine. Serum creatinine level was obtained directly from laboratory results. Clinical significance was judged by the investigator based upon the out of range values of standard range set for parameter. Any change in serum creatinine assessments which were deemed clinically significant by the investigator was reported.</description>
        <time_frame>From start of study drug administration to end of study (Week 56)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84).</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT])/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change in Serum Creatinine Value</title>
          <description>eGFR was assessed by measuring serum creatinine. Serum creatinine level was obtained directly from laboratory results. Clinical significance was judged by the investigator based upon the out of range values of standard range set for parameter. Any change in serum creatinine assessments which were deemed clinically significant by the investigator was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Positive Anti-Parathyroid Hormone Antibodies at Week 24</title>
        <description>Number of participants with positive anti-parathyroid hormone antibodies at Week 24 was reported.</description>
        <time_frame>Week 24</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;overall number of participants analyzed&quot; were participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT])/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Anti-Parathyroid Hormone Antibodies at Week 24</title>
          <description>Number of participants with positive anti-parathyroid hormone antibodies at Week 24 was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;overall number of participants analyzed&quot; were participants who were evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Albumin Corrected Serum Calcium (ACSC) Concentration at Weeks 24 and 52 (EOT)</title>
        <description>Change from baseline in ACSC concentration at Weeks 24 and 52 (EOT) was reported.</description>
        <time_frame>Baseline, Weeks 24 and 52 (EOT)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT])/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Albumin Corrected Serum Calcium (ACSC) Concentration at Weeks 24 and 52 (EOT)</title>
          <description>Change from baseline in ACSC concentration at Weeks 24 and 52 (EOT) was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.024" spread="0.2065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52 (EOT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.076" spread="0.1497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Phosphate Concentration at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)</title>
        <description>Change from baseline in serum phosphate concentration at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT) was reported.</description>
        <time_frame>Baseline, Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT])/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Phosphate Concentration at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)</title>
          <description>Change from baseline in serum phosphate concentration at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT) was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.167" spread="0.1816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.124" spread="0.2252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.107" spread="0.2583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.160" spread="0.2303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.089" spread="0.1809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.121" spread="0.2542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52 (EOT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.114" spread="0.2590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ACSC-phosphate Product at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)</title>
        <description>Change from baseline in ACSC-phosphate product at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT) was reported. Here &quot;mmol^2/L^2&quot; is abbreviated as millimoles square per liter square.</description>
        <time_frame>Baseline, Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT])/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ACSC-phosphate Product at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)</title>
          <description>Change from baseline in ACSC-phosphate product at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT) was reported. Here &quot;mmol^2/L^2&quot; is abbreviated as millimoles square per liter square.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>mmol^2/L^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52 (EOT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 24-hour Urine Calcium Excretion at Weeks 16, 32 and 52 (EOT)</title>
        <description>Change from baseline in 24-hour urine calcium excretion at Weeks 16, 32 and 52 (EOT) was reported.</description>
        <time_frame>Baseline, Weeks 16, 32 and 52 (EOT)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;overall number of participants analyzed&quot; were participants who were evaluable for this outcome measure and &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT])/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 24-hour Urine Calcium Excretion at Weeks 16, 32 and 52 (EOT)</title>
          <description>Change from baseline in 24-hour urine calcium excretion at Weeks 16, 32 and 52 (EOT) was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;overall number of participants analyzed&quot; were participants who were evaluable for this outcome measure and &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>millimoles per day (mmol/day)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="4.741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.13" spread="4.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52 (EOT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.53" spread="4.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Prescribed Supplemental Oral Calcium Dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (End of Study [EOS])</title>
        <description>Percentage change from baseline in prescribed supplemental oral calcium dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS) were reported.</description>
        <time_frame>Baseline and at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points. Data for Week 56 was not collected as study was early terminated due to FDA recall of rhPTH(1-84) (Natpara).</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT])/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Prescribed Supplemental Oral Calcium Dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (End of Study [EOS])</title>
          <description>Percentage change from baseline in prescribed supplemental oral calcium dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS) were reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points. Data for Week 56 was not collected as study was early terminated due to FDA recall of rhPTH(1-84) (Natpara).</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.30" spread="34.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.08" spread="38.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.94" spread="45.665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.05" spread="49.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.58" spread="44.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.36" spread="45.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 52 (EOT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.55" spread="45.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 56 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Prescribed Supplemental Active Vitamin D Dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS)</title>
        <description>Percentage change from baseline in prescribed supplemental oral calcium dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS) were reported.</description>
        <time_frame>Baseline, Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;overall number of participants analyzed&quot; were participants who were evaluable for this outcome measure and &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points. Data for Week 56 was not collected as study was early terminated due to FDA recall of rhPTH(1-84) (Natpara).</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT])/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Prescribed Supplemental Active Vitamin D Dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS)</title>
          <description>Percentage change from baseline in prescribed supplemental oral calcium dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS) were reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;overall number of participants analyzed&quot; were participants who were evaluable for this outcome measure and &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points. Data for Week 56 was not collected as study was early terminated due to FDA recall of rhPTH(1-84) (Natpara).</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.50" spread="40.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.00" spread="39.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-80.83" spread="27.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-85.42" spread="25.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-90.79" spread="17.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-90.10" spread="18.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 52 (EOT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77.38" spread="43.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 56 (EOS)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Serum Bone-specific Alkaline Phosphatase at Weeks 8, 24 and 52 (EOT)</title>
        <description>Percentage change from baseline in serum bone-specific alkaline phosphatase at Weeks 8, 24 and 52 (EOT) was reported.</description>
        <time_frame>Baseline, Weeks 8, 24 and 52 (EOT)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT])/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Serum Bone-specific Alkaline Phosphatase at Weeks 8, 24 and 52 (EOT)</title>
          <description>Percentage change from baseline in serum bone-specific alkaline phosphatase at Weeks 8, 24 and 52 (EOT) was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.90" spread="31.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.14" spread="54.452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 52 (EOT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.08" spread="75.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Serum Osteocalcin at Weeks 8, 24 and 52 (EOT)</title>
        <description>Percentage change from baseline in serum osteocalcin at Weeks 8, 24 and 52 (EOT) was reported.</description>
        <time_frame>Baseline, Weeks 8, 24 and 52 (EOT)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT])/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Serum Osteocalcin at Weeks 8, 24 and 52 (EOT)</title>
          <description>Percentage change from baseline in serum osteocalcin at Weeks 8, 24 and 52 (EOT) was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.74" spread="68.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225.91" spread="130.798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 52 (EOT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294.93" spread="215.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Procollagen 1 N-Terminal Propeptide at Weeks 8, 24 and 52 (EOT)</title>
        <description>Percentage change from baseline in procollagen 1 N-terminal propeptide at Weeks 8, 24 and 52 (EOT) was reported.</description>
        <time_frame>Baseline, Weeks 8, 24 and 52 (EOT)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT])/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Procollagen 1 N-Terminal Propeptide at Weeks 8, 24 and 52 (EOT)</title>
          <description>Percentage change from baseline in procollagen 1 N-terminal propeptide at Weeks 8, 24 and 52 (EOT) was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>percentage change</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.98" spread="161.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412.46" spread="248.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 52 (EOT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="476.07" spread="377.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Type I Collagen C-Telopeptides at Weeks 8, 24 and 52 (EOT)</title>
        <description>Percentage change from baseline in type I collagen C-telopeptides at Week 8, 24 and 52 (EOT) was reported.</description>
        <time_frame>Baseline, Weeks 8, 24 and 52 (EOT)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT])/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Type I Collagen C-Telopeptides at Weeks 8, 24 and 52 (EOT)</title>
          <description>Percentage change from baseline in type I collagen C-telopeptides at Week 8, 24 and 52 (EOT) was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.62" spread="160.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.26" spread="198.947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 52 (EOT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227.13" spread="182.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Type I Collagen N-Telopeptides at Weeks 8, 24 and 52 (EOT)</title>
        <description>Percentage change from baseline in type I collagen N-telopeptides at Week 8, 24 and 52 (EOT) was reported.</description>
        <time_frame>Baseline, Weeks 8, 24 and 52 (EOT)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT])/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Type I Collagen N-Telopeptides at Weeks 8, 24 and 52 (EOT)</title>
          <description>Percentage change from baseline in type I collagen N-telopeptides at Week 8, 24 and 52 (EOT) was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;number analyzed&quot; were participants who were evaluable for the outcome measure at given time points.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.33" spread="99.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.23" spread="160.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage change at Week 52 (EOT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231.80" spread="270.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Positive Anti-Parathyroid Hormone Antibodies at Week 52 (EOT)</title>
        <description>Number of participants with positive anti-parathyroid hormone antibodies at Week 52 (EOT) was reported.</description>
        <time_frame>Week 52 (EOT)</time_frame>
        <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;overall number of participants analyzed&quot; were participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>rhPTH(1-84)</title>
            <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Anti-Parathyroid Hormone Antibodies at Week 52 (EOT)</title>
          <description>Number of participants with positive anti-parathyroid hormone antibodies at Week 52 (EOT) was reported.</description>
          <population>Safety analysis population consisted of all participants who had received at least 1 dose of rhPTH(1-84). Here &quot;overall number of participants analyzed&quot; were participants who were evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of screening up to end of study (Week 56)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>rhPTH(1-84)</title>
          <description>Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was &gt;2.25 mmol/L (&gt;9.0 mg/dL), a starting dose of 25 mcg was administered.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated due to Takeda commercial Natpara recall.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Shire</organization>
      <phone>+1 866 842 5335</phone>
      <email>ClinicalTransparency@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

